Gilead’s Yescarta Growth Continues, But Momentum Slowed

Yescarta brought in $75m in the third quarter, up 10% sequentially, and well above the $20m tallied by competitor Kymriah. Gilead also saw continued HIV sales growth, with HCV sales in line with expectations.